Participant flow

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) · Source last updated 2025-08-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Participants received retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

   id

   FG000

   title

   Retifanlimab 500 mg

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         70

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         7

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         94

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         17

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         77

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 94 participants with locally advanced or metastatic squamous carcinoma of the anal canal were enrolled in the study and treated with retifanlimab.

recruitment Details

This study was conducted at 40 study centers: 32 in France, 19 in the United Kingdom, 10 in Italy, 10 in Spain, 7 in Denmark, 6 in the United States, 4 in Norway, 4 in Belgium, and 2 in Germany.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice